DK1133477T3 - Substituerede benzimidazoler og deres anvendelse som parpinhibitorer - Google Patents

Substituerede benzimidazoler og deres anvendelse som parpinhibitorer

Info

Publication number
DK1133477T3
DK1133477T3 DK99964497T DK99964497T DK1133477T3 DK 1133477 T3 DK1133477 T3 DK 1133477T3 DK 99964497 T DK99964497 T DK 99964497T DK 99964497 T DK99964497 T DK 99964497T DK 1133477 T3 DK1133477 T3 DK 1133477T3
Authority
DK
Denmark
Prior art keywords
inhibitors
pair
substituted benzimidazoles
benzimidazoles
substituted
Prior art date
Application number
DK99964497T
Other languages
Danish (da)
English (en)
Inventor
Wilfried Lubisch
Michael Kock
Thomas Hoeger
Sabine Schult
Roland Grandel
Reinhold Mueller
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999116460 external-priority patent/DE19916460B4/de
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of DK1133477T3 publication Critical patent/DK1133477T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK99964497T 1998-11-27 1999-11-23 Substituerede benzimidazoler og deres anvendelse som parpinhibitorer DK1133477T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19854933 1998-11-27
DE1999116460 DE19916460B4 (de) 1999-04-12 1999-04-12 Substituierte Benzimidazole, deren Herstellung und Anwendung
PCT/EP1999/009004 WO2000032579A1 (de) 1998-11-27 1999-11-23 Substituierte benzimidazole und ihre verwendung als parp inhibitoren

Publications (1)

Publication Number Publication Date
DK1133477T3 true DK1133477T3 (da) 2004-06-21

Family

ID=26050434

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99964497T DK1133477T3 (da) 1998-11-27 1999-11-23 Substituerede benzimidazoler og deres anvendelse som parpinhibitorer

Country Status (32)

Country Link
US (2) US6448271B1 (cs)
EP (1) EP1133477B1 (cs)
JP (1) JP3432800B2 (cs)
KR (1) KR100417779B1 (cs)
CN (1) CN1184208C (cs)
AR (1) AR021400A1 (cs)
AT (1) ATE259789T1 (cs)
AU (1) AU764216B2 (cs)
BG (1) BG65047B1 (cs)
BR (1) BR9915701A (cs)
CA (1) CA2352554C (cs)
CZ (1) CZ300148B6 (cs)
DE (1) DE59908600D1 (cs)
DK (1) DK1133477T3 (cs)
ES (1) ES2216625T3 (cs)
HK (1) HK1042084B (cs)
HR (1) HRP20010484B1 (cs)
HU (1) HUP0200749A3 (cs)
IL (2) IL143303A0 (cs)
MY (1) MY128488A (cs)
NO (1) NO20012570L (cs)
NZ (1) NZ511825A (cs)
PL (1) PL196367B1 (cs)
PT (1) PT1133477E (cs)
RU (1) RU2001117757A (cs)
SI (1) SI1133477T1 (cs)
SK (1) SK285529B6 (cs)
TR (1) TR200101498T2 (cs)
TW (1) TWI247741B (cs)
UA (1) UA61158C2 (cs)
WO (1) WO2000032579A1 (cs)
ZA (1) ZA200104118B (cs)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
WO2000026192A1 (de) 1998-11-03 2000-05-11 Basf Aktiengesellschaft Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
WO2001021615A1 (en) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
FR2812878B1 (fr) * 2000-08-08 2002-10-11 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
AR030121A1 (es) * 2000-08-08 2003-08-13 Sanofi Aventis Derivados de benzimidazol, su preparacion y su aplicacion en terapeutica
FR2816941B1 (fr) * 2000-11-23 2003-01-31 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816942B1 (fr) 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO2002068407A1 (fr) * 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Compose benzimidazole
WO2002072090A1 (en) 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US20040242635A1 (en) * 2001-03-30 2004-12-02 Painter Rachel J. Encapsulated dyes in cosmetic compositions
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
DE50310378D1 (de) 2002-07-26 2008-10-02 Basf Plant Science Gmbh Neue selektionsverfahren
JPWO2004014873A1 (ja) * 2002-08-09 2005-12-02 杏林製薬株式会社 ４−置換キナゾリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
JP2006505570A (ja) 2002-10-17 2006-02-16 アムジエン・インコーポレーテツド ベンズイミダゾール誘導体およびそれのバニロイド受容体リガンドとしての使用
HU0301154D0 (en) * 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
US8088971B2 (en) 2005-03-08 2012-01-03 Basf Plant Science Gmbh Expression enhancing intron sequences
EP1863771B1 (en) * 2005-03-14 2012-11-07 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
AU2012200399B2 (en) * 2005-04-11 2013-07-11 Abbvie Ireland Unlimited Company 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
JP2008543786A (ja) * 2005-06-10 2008-12-04 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ調節因子及び癌の治療
US7825543B2 (en) 2005-07-12 2010-11-02 Massachusetts Institute Of Technology Wireless energy transfer
CN101860089B (zh) 2005-07-12 2013-02-06 麻省理工学院 无线非辐射能量传递
BRPI0613783A2 (pt) * 2005-07-18 2011-02-01 Bipar Sciences Inc tratamento de cáncer
WO2007041357A1 (en) 2005-09-29 2007-04-12 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
EP1779849A1 (en) * 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of septic shock
DE602006013191D1 (de) 2005-11-15 2010-05-06 Abbott Lab Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
US20080293795A1 (en) * 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
US20080280867A1 (en) * 2006-01-17 2008-11-13 Abbott Laboratories Combination therapy with parp inhibitors
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
US20090029966A1 (en) * 2006-01-17 2009-01-29 Abbott Laboratories Combination therapy with parp inhibitors
DK2338487T3 (da) * 2006-01-17 2013-12-09 Abbvie Bahamas Ltd Kombinationsterapi med PARP-inhibitorer
AU2007232297B2 (en) * 2006-04-03 2012-09-20 Msd Italia S.R.L. Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors
US20070259937A1 (en) * 2006-05-02 2007-11-08 Giranda Vincent L Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
AU2007354301A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with PARP inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2059498A4 (en) * 2006-09-05 2011-01-12 Bipar Sciences Inc TREATMENT OF CANCER
CN102379884A (zh) * 2006-09-05 2012-03-21 彼帕科学公司 Parp抑制剂对脂肪酸合成的抑制及其治疗方法
WO2008084261A1 (en) 2007-01-10 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008239659B2 (en) * 2007-04-13 2013-09-05 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
US8138168B1 (en) * 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
EP2727921B1 (en) * 2007-10-12 2017-04-19 AbbVie Ireland Unlimited Company 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 2
NZ586125A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
KR20100102607A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법
WO2009087381A1 (en) 2008-01-08 2009-07-16 Merck Sharp & Dohme Ltd Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
EP2247600A4 (en) * 2008-02-06 2011-09-14 Biomarin Pharm Inc INHIBITORS BASED ON BENZOXAZOLE-CARBOXAMIDE COMPOUNDS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) ACTIVITY
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
CN102725412B (zh) 2009-11-27 2017-09-22 巴斯夫植物科学有限公司 优化的内切核酸酶及其用途
JP5922029B2 (ja) 2009-11-27 2016-05-24 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー キメラエンドヌクレアーゼおよびその使用
CA2781835A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
WO2011107504A1 (de) 2010-03-04 2011-09-09 Bayer Cropscience Ag Fluoralkyl- substituierte 2 -amidobenzimidazole und deren verwendung zur steigerung der stresstoleranz in pflanzen
CA2833914A1 (en) * 2011-05-10 2012-11-15 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
WO2013014038A1 (en) * 2011-07-26 2013-01-31 Nerviano Medical Sciences S.R.L. 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors
EP2561759A1 (en) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102617502A (zh) * 2012-03-19 2012-08-01 江苏先声药物研究有限公司 一类苯并噁唑衍生物及其医药应用
WO2014037340A1 (de) 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
CN104230897B (zh) * 2013-06-17 2016-07-06 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN104230898B (zh) * 2013-06-17 2016-06-29 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN103396405A (zh) * 2013-08-21 2013-11-20 中国药科大学 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
CN103483322A (zh) * 2013-08-21 2014-01-01 中国药科大学 5-氟-1h-苯并咪唑-4-甲酰胺衍生物、其制法及医药用途
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
US11384081B2 (en) 2016-09-20 2022-07-12 Centre Leon Berard Benzoimidazole derivatives as anticancer agents
US20200261470A1 (en) 2016-11-02 2020-08-20 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
CN109232540A (zh) * 2018-06-15 2019-01-18 深圳市坤健创新药物研究院 一种取代苯并咪唑衍生物及应用
CN108997320A (zh) * 2018-08-30 2018-12-14 深圳市坤健创新药物研究院 一种含氟取代苯并咪唑衍生物及应用
EP3860988A1 (en) 2018-10-03 2021-08-11 Tesaro, Inc. Crystalline forms of niraparib freebase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1354554U (cs)
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
CZ30398A3 (cs) 1995-08-02 1998-06-17 Newcastle University Ventures Limited Benzimidazolové sloučeniny, farmaceutický prostředek obsahující tyto sloučeniny a použití těchto sloučenin jako chemoterapeutických činidel
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
GB9702701D0 (en) * 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake

Also Published As

Publication number Publication date
AU764216B2 (en) 2003-08-14
WO2000032579A1 (de) 2000-06-08
IL143303A0 (en) 2002-04-21
ATE259789T1 (de) 2004-03-15
CN1184208C (zh) 2005-01-12
BG65047B1 (bg) 2007-01-31
KR20010080596A (ko) 2001-08-22
RU2001117757A (ru) 2004-02-27
JP3432800B2 (ja) 2003-08-04
EP1133477A1 (de) 2001-09-19
CZ20011855A3 (cs) 2001-08-15
ES2216625T3 (es) 2004-10-16
BG105596A (en) 2002-02-28
USRE39608E1 (en) 2007-05-01
PT1133477E (pt) 2004-06-30
AU3034300A (en) 2000-06-19
HUP0200749A2 (en) 2002-08-28
HK1042084A1 (en) 2002-08-02
NZ511825A (en) 2003-08-29
UA61158C2 (uk) 2003-11-17
PL347884A1 (en) 2002-04-22
IL143303A (en) 2006-12-10
HK1042084B (zh) 2005-09-02
HRP20010484A2 (en) 2003-04-30
CA2352554A1 (en) 2000-06-08
BR9915701A (pt) 2001-08-14
HRP20010484B1 (hr) 2010-08-31
KR100417779B1 (ko) 2004-02-05
HUP0200749A3 (en) 2003-03-28
TR200101498T2 (tr) 2001-11-21
SK285529B6 (sk) 2007-03-01
TWI247741B (en) 2006-01-21
NO20012570L (no) 2001-07-13
AR021400A1 (es) 2002-07-17
CA2352554C (en) 2006-10-10
SI1133477T1 (en) 2004-06-30
EP1133477B1 (de) 2004-02-18
MY128488A (en) 2007-02-28
SK7142001A3 (en) 2001-12-03
CZ300148B6 (cs) 2009-02-25
US6448271B1 (en) 2002-09-10
ZA200104118B (en) 2002-05-21
JP2002531442A (ja) 2002-09-24
NO20012570D0 (no) 2001-05-25
CN1332731A (zh) 2002-01-23
DE59908600D1 (de) 2004-03-25
PL196367B1 (pl) 2007-12-31

Similar Documents

Publication Publication Date Title
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO991922D0 (no) Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1204649T3 (da) Arylmethylcarbonylaminothiazolderivater og deres anvendelse som antitumormidler
NO20013452L (no) Benzoheterocykler og deres anvendelse som MEK-inhibitorer
NO20021253L (no) Kinolylpropylpiperidinderivater og deres anvendelse som antibakterielle midler
NO20021449L (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
DK1282611T3 (da) Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
NO20012688L (no) Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer
DK1478629T3 (da) N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
NO20032830L (no) Tetrahydropyridinderivater, fremstilling derav og anvendelse som celleproliferasjonsinhibitorer
NO20025150D0 (no) 2-acylindolderivater og deres anvendelse som antitumormidler
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
NO20005400D0 (no) Kinoloner anvendt som MRS-inhibitorer og baktericider
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20032490D0 (no) Substituerte 2-anilin-benzimidazoler og deres anvendelse som NHE-inhibitorer
NO995513D0 (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-A agonister
DK1150996T3 (da) Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
NO20034434D0 (no) Indolinoner substituert i 6-stilling og deres anvendelse som kinase-inhibitorer
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20023951D0 (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
NO20030813L (no) Bifenylderivater og deres anvendelse som integrininhibitorer